KEY TAKEAWAYS
- The study aimed to investigate the treatment patterns and burden of illness among older pts with MCL in Canada.
- Researchers concluded that the substantial burden of newly diagnosed MCL pts on the healthcare system is evident, highlighting the urgent need for improved treatment strategies.
Peter Anglin and his team aimed to assess the current landscape of Mantle Cell Lymphoma (MCL) treatment and the associated burden of illness in elderly patients (pts) across Canada, ultimately contributing to more informed and effective decision-making.
Researchers performed an inclusive retrospective study utilizing administrative data, wherein individuals aged ≥65 newly diagnosed with MCL between January 1, 2013, and December 31, 2016, were matched with general population controls. Cases were systematically followed for up to 3 years, allowing for the assessment of healthcare resource utilization (HCRU), healthcare costs, time to next treatment or death (TTNTD), and overall survival (OS). The data were further stratified based on the first-line treatment.
About 159 MCL pts were meticulously matched with 636 controls in this study. Direct healthcare costs peaked in the first year post-diagnosis for MCL pts (Y1: CAD 77,555 ± 40,789), subsequently decreasing (Y2: CAD 40,093 ± 28,720; Y3: CAD 36,059 ± 36,303), consistently surpassing costs for controls. The 3-year OS rate after MCL diagnosis stood at 68.6%, with pts receiving bendamustine + rituximab (BR) demonstrating a significantly higher OS compared to other regimens (72.4% vs. 55.6%, P = 0.041). Notably, 40.9% of MCL pts initiated a second-line therapy or succumbed within 3 years.
The study concluded that newly diagnosed MCL imposes a significant burden on the healthcare system, with nearly half of all pts progressing to second-line therapy or succumbing within 3 years.
The study is sponsored by Janssen Inc.
Source: https://pubmed.ncbi.nlm.nih.gov/37366901/
Anglin P, Elia-Pacitti J, Eberg M, et al (2024). “Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada.” Curr Oncol. 2023 Jun 8;30(6):5529-5545. doi: 10.3390/curroncol30060418. PMID: 37366901; PMCID: PMC10297405.
